Wheeler Bio to Support MindImmune’s Alzheimer’s Prevention Program

Wheeler Bio, a U.S.-based contract development and biomanufacturing organization (CDMO), has entered into an agreement with MindImmune Therapeutics, a biopharmaceutical company focused on neuroinflammation and Alzheimer’s disease. 

Under the agreement, Wheeler Bio will provide integrated process development and cGMP drug substance manufacturing services via its ModularCMC platform specializing in antibody-based modalities to support the advancement of the MITI-101 program, MindImmune’s lead monoclonal antibody (mAb) program under development for the treatment of Alzheimer’s disease.

MITI-101 is designed to block CD11c+ immune cell recruitment from the blood into the brain and to prevent their pathologic effects in Alzheimer’s disease. The mAb is a first-in-class approach targeting the trafficking of peripheral immune cells into the brain, a key driver of neuroinflammation believed to underlie Alzheimer’s and other neurodegenerative disorders.

Wheeler’s ModularCMC platform is designed to streamline the path from discovery to clinical study initiation, with agility and scalability.

“We are thrilled to establish this partnership with MindImmune to advance this promising therapeutic focused on a disease where there is significant unmet medical need,” said Patrick Lucy, President & CEO of Wheeler Bio. “MindImmune previously worked with Alloy Therapeutics in the discovery phase and their selection of Wheeler to support their CMC efforts will enable them to take advantage of the significant economic incentives provided by the Wheeler-Alloy partnership.”

“MITI-101 represents a first-in-class strategy to stop harmful innate immune cells from driving brain inflammation in Alzheimer’s and other neurodegenerative diseases. By blocking the infiltration of innate immune cells into the brain, MITI-101 offers a new way to target neuroinflammation — and partnering with Wheeler Bio enables us to advance this groundbreaking science into the clinic with urgency, bringing new hope to patients and families facing these devastating illnesses,” said Stevin Zorn, President and CEO of Mindimmune Therapeutics, Inc.